scholarly journals Pure laparoscopic versus open right hepatectomy in living liver donors: which is longer bench-surgery time

2020 ◽  
Vol 34 (1) ◽  
pp. S137-S137
Author(s):  
Kwangpyo Hong ◽  
Suk Kyun Hong ◽  
Eui Soo Han ◽  
Sanggyun Suh ◽  
Su young Hong ◽  
...  
Keyword(s):  
Right Hepatectomy ◽  
Living Liver Donors ◽  
Bench Surgery ◽  
Liver Donors

scholarly journals Pure Laparoscopic vs. Open Right Hepatectomy in Living Liver Donors: Bench-Surgery Time

2021 ◽  
Vol 8 ◽  
Author(s):  
Kwangpyo Hong ◽  
Suk Kyun Hong ◽  
Eui Soo Han ◽  
Sanggyun Suh ◽  
Su young Hong ◽  
...  
Keyword(s):  
Medical Records ◽  
Right Hepatectomy ◽  
Donor Hepatectomy ◽  
Graft Donor ◽  
Recorded Data ◽  
The Mean ◽  
Laparoscopic Assisted ◽  
Living Liver Donors ◽  
Bench Surgery ◽  
Liver Donors

Background: Recently, there have been several reports on pure laparoscopic donor right hepatectomy (PLDRH), but the effect of pure laparoscopy on bench surgery has not been evaluated. This study aimed to compare bench-surgery time between PLDRH and conventional donor right hepatectomy (CDRH).Methods: We retrospectively reviewed the medical records of 758 live liver donors between January 2012 and December 2019. We divided the patients into two groups: between January 2012 and September 2015, when we exclusively performed CDRH, and between March 2016 and December 2019, when PLDRH was standardized. We excluded all other types of graft donor hepatectomy, laparoscopic assisted donor hepatectomy, and cases with no recorded data.Results: In total, 267 donors were included in the PLDRH group and were compared with 247 donors in the CDRH group. Similar proportions of graft vascular variations were observed between the two groups. The mean bench-surgery time was longer in the PLDRH group than in the CDRH group (49.3 ± 19.9 vs. 39.5 ± 17.5 min; P < 0.001).Conclusion: The bench-surgery time was longer in the PLDRH group than the CDRH group, regardless of whether the vascular network was reconstructed. Expertise in bench-surgery as well as donor surgery and recipient surgery is mandatory for PLDRH to be safe and feasible.

scholarly journals Pure laparoscopic versus open right hepatectomy in living liver donors: bench-surgery time and graft weight discrepancy

2021 ◽  
Vol 35 (1) ◽  
pp. S142-S142
Author(s):  
Kwangpyo Hong ◽  
Suk Kyun Hong ◽  
Eui Soo Han ◽  
Sanggyun Suh ◽  
Su young Hong ◽  
...  
Keyword(s):  
Right Hepatectomy ◽  
Graft Weight ◽  
Living Liver Donors ◽  
Bench Surgery ◽  
Liver Donors

Outcome of Right Hepatectomy for Living Liver Donors: A Single Egyptian Center Experience

2012 ◽  
Vol 16 (6) ◽  
pp. 1181-1188 ◽  
Author(s):  
Tarek Salah ◽  
Ahmad M. Sultan ◽  
Omar M. Fathy ◽  
Mohammed M. Elshobary ◽  
Nabieh A. Elghawalby ◽  
...  
Keyword(s):  
Right Hepatectomy ◽  
Living Liver Donors ◽  
Liver Donors

Safety of modified extended right hepatectomy in living liver donors

2007 ◽  
Vol 20 (9) ◽  
pp. 779-783 ◽  
Author(s):  
Eung-Ho Cho ◽  
Kyung-Suk Suh ◽  
Hae W. Lee ◽  
Woo Y. Shin ◽  
Nam-Joon Yi ◽  
...  
Keyword(s):  
Right Hepatectomy ◽  
Extended Right Hepatectomy ◽  
Living Liver Donors ◽  
Liver Donors

scholarly journals One- Week Prophylaxis with Enoxaparin after Hospital Discharge Is Effective in Preventing Venous Thromboembolism in Living Liver Donors- Single Institution Retrospective Analysis

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 2442-2442
Author(s):  
Leila Khaddour ◽  
Zaid Al Saheli ◽  
Yaser Alkhatib ◽  
Marwan Abouljoud ◽  
Philip Kuriakose
Keyword(s):  
Venous Thromboembolism ◽  
Factor V Leiden ◽  
Antiphospholipid Antibody ◽  
Factor V ◽  
Right Hepatectomy ◽  
At Iii ◽  
Thrombophilia Screening ◽  
Liver Donation ◽  
Living Liver Donors ◽  
Liver Donors

Background: Living donor liver transplant (LDLT) has expanded organ availability to patients with advanced liver failure. While this procedure decreased morbidity and mortality in recipients, it could pose a risk to the donors. Deep vein thrombosis and pulmonary embolism are known postoperative complications associated with morbidity and mortality in living liver donors. At our institution thrombophilia screening starts during donor selection process with antiphospholipid antibody panel and screening coagulation tests for all candidates. This is followed by hematology evaluation to determine the need for inherited thrombophilia screening and accordingly, hypercoagulability risk. Additionally, the institution strategy for venous thromboembolism (VTE) prevention in liver donors involves prophylactic subcutaneous heparin within 24 hours of the surgery and maintained until discharge followed by enoxaparin for 7 days after discharge. We conducted this retrospective analysis to evaluate the efficacy of these measures in reducing the rate of VTE in this population. Methods: Retrospective electronic medical chart review to analyze data on living liver donors in our institution between January 2000 and February 2019. Inclusion criteria: all adult living liver donors who underwent partial right hepatectomy and followed for at least 6 weeks after surgery. The primary endpoint is the rate of VTE within 6 weeks of liver donation in patients who received post-discharge enoxaparin for one week in comparison to donors who did not receive enoxaparin. Secondary endpoints: re-admission rate and bleeding events. All continuous data was presented using means, medians and standard deviation, while categorical data were presented using counts and percentages. Results: At our institution 112 liver donors underwent right hepatectomy. Baseline characteristics (Table-1): The average age was 34 years, 58% were females and 86% were white. 10% of donors reported family history of DVT/PE. 90% of donors were screened for antiphospholipid antibody syndrome, with one case with positive titers. 34% of donors were screened for protein C (PC), Protein S (PS) and Antithrombin deficiency (AT-III). There were no cases of PC or AT-III deficiency, but one case of mild PS deficiency was identified. 38% cases were screened for factor V Leiden and prothrombin mutations, with 3 donors carrying heterozygous factor V Leiden mutation and one with heterozygous prothrombin mutation. All donors received prophylactic heparin during their stay in the hospital. A total of 15 donors had coagulation factors checked before and after the surgery. Post operatively, there was significant transient deficiency in PC, PS and AT-III, as well as significant increase in factor VIII level. This imbalance peaked within one week of surgery, with PC mean activity of 48%, PS mean activity of 48%, AT-III mean activity of 53% and FVIII of 290%. Factor activities started to recover by third week of surgery and returned to baseline within 8 weeks (figure 1). A total of 100 patients received one week of prophylaxis with Enoxaparin after being discharged from the hospital (Table-2). There was no VTE incidents in this group. 14/100 were readmitted to the hospital within 6 weeks of initial hospital admission; none due to bleeding. A total of 12 patients did not receive any pharmacological preventive measures upon discharge; due to in-hospital bleeding in 3 cases, prior to starting this strategy in 4 cases, unknown reason in 5 cases. VTE events and subsequent readmissions occurred in 2/12 (16.7%) (figure 2). Odds ratio could not be performed due to the very small number of patients in the comparison group (Table-2). Conclusion: Partial hepatectomy for liver donation is associated with significant remote hypercoagulable state due to the sudden loss in liver volume and concomitant transient deficiency of PC, PS and AT-III as well as increasing Factor VIII activity. This thrombophilia peaks within one week after the surgery and starts to recover by the third week. Clinicians should consider performing baseline thrombophilia screening and subsequently exclude potential donors with preexisting hypercoagulable state. Extending pharmacological VTE prevention with enoxaparin for 7 days after hospital discharge has been successful in reducing the VTE risk without increasing risk of bleeding or readmission rate in our patient population. Disclosures Kuriakose: Alexion: Consultancy, Honoraria, Speakers Bureau; Bayer: Consultancy.

Respiratory Complications: A Major Concern after Right Hepatectomy in Living Liver Donors

2006 ◽  
Vol 81 (2) ◽  
pp. 181-186 ◽  
Author(s):  
Federica Dondero ◽  
Camille Taill?? ◽  
Herv?? Mal ◽  
Daniele Sommacale ◽  
Alain Sauvanet ◽  
...  
Keyword(s):  
Right Hepatectomy ◽  
Respiratory Complications ◽  
Living Liver Donors ◽  
Liver Donors

scholarly journals First, do no harm: The question of liver biopsy in living liver donors

2008 ◽  
Vol 14 (4) ◽  
pp. 420-422 ◽  
Author(s):  
Kim M. Olthoff ◽  
K. Rajender Reddy
Keyword(s):  
Liver Biopsy ◽  
Do No Harm ◽  
Living Liver Donors ◽  
Liver Donors

Feasibility of semiautomated MR volumetry using gadoxetic acid-enhanced MRI at hepatobiliary phase for living liver donors

2013 ◽  
Vol 72 (3) ◽  
pp. 640-645 ◽  
Author(s):  
Jeongjin Lee ◽  
Kyoung Won Kim ◽  
So Yeon Kim ◽  
Bohyoung Kim ◽  
So Jung Lee ◽  
...  
Keyword(s):  
Gadoxetic Acid ◽  
Hepatobiliary Phase ◽  
Enhanced Mri ◽  
Living Liver Donors ◽  
Mr Volumetry ◽  
Liver Donors
Sign in / Sign up

Export Citation Format

Share Document